CompletedPhase 2

A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum

United States10 participantsStarted 2014-01-31

Plain-language summary

The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Treatment with any biologicals (including intravenous immunoglobulin) or investigational agents within the last 4 weeks (or 5 half-lives, whichever is longer).
✕. Treatment with corticosteroids or cyclosporine within the last 2 weeks.

Change in Physician's Wound Assessment & Patient's Global Assessment

Timeframe: 28 days

NCT IDNCT01965613

SponsorJanssen Research & Development, LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2016-12-31